← Back to Screener
Co-Diagnostics, Inc. Common Stock (CODX)
Price$6.20
Value ScoreC
Growth ScoreD
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-27.72%
Price vs S&P 500 (4W)445.35%
VGM Score54.02
Market Capitalization$22.88M
All Metrics
Book Value / Share (Quarterly)$4.45
P/TBV (Annual)0.77x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-73.70%
Cash Flow / Share (Quarterly)$-8.05
Price vs S&P 500 (YTD)57.64%
Gross Margin (TTM)45.06%
Net Profit Margin (TTM)-6753.75%
EPS (TTM)$-29.39
10-Day Avg Trading Volume31.77M
EPS Excl Extra (TTM)$-29.39
Revenue Growth (5Y)-61.60%
EPS (Annual)$-35.25
ROI (Annual)-227.33%
Gross Margin (Annual)64.28%
Net Profit Margin (5Y Avg)-1803.56%
Cash / Share (Quarterly)$2.28
Revenue Growth QoQ (YoY)190.27%
ROA (Last FY)-189.54%
Revenue Growth TTM (YoY)-79.47%
EBITD / Share (TTM)$-30.49
ROE (5Y Avg)-64.69%
Operating Margin (TTM)-7053.82%
Cash Flow / Share (Annual)$-14.24
P/B Ratio1.43x
P/B Ratio (Quarterly)0.42x
Net Income / Employee (Annual)$-407,800
EV / Revenue (TTM)20.39x
Net Interest Coverage (TTM)121.11x
ROA (TTM)-141.15%
EV / EBITDA (TTM)0.83x
EPS Incl Extra (Annual)$-35.25
Current Ratio (Annual)3.87x
Quick Ratio (Quarterly)1.94x
3-Month Avg Trading Volume4.50M
52-Week Price Return-1.27%
Revenue / Employee (TTM)$6,200
Tangible BV / Share (Quarterly)$2.45
P/S Ratio (Annual)36.75x
Asset Turnover (Annual)0.03x
52-Week High$46.50
Operating Margin (5Y Avg)-1910.89%
EPS Excl Extra (Annual)$-35.25
CapEx CAGR (5Y)-1.89%
Tangible BV CAGR (5Y)-27.45%
26-Week Price Return-11.79%
Quick Ratio (Annual)3.42x
13-Week Price Return267.67%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.28x
Enterprise Value$14.64M
Revenue / Share Growth (5Y)-29.37%
Asset Turnover (TTM)0.02x
Book Value / Share Growth (5Y)33.38%
Revenue / Employee (Annual)$5,400
Inventory Turnover (Annual)0.22x
Pretax Margin (Annual)-7793.20%
Cash / Share (Annual)$5.67
3-Month Return Std Dev352.64%
Gross Margin (5Y Avg)69.90%
Net Income / Employee (TTM)$-421,800
ROE (Last FY)-227.33%
Net Interest Coverage (Annual)-2126.85x
EPS Basic Excl Extra (Annual)$-35.25
P/FCF (TTM)1.61x
Receivables Turnover (TTM)6.57x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-29.39
Receivables Turnover (Annual)3.85x
ROI (TTM)-164.92%
P/S Ratio (TTM)31.85x
Pretax Margin (5Y Avg)-1864.20%
Revenue / Share (Annual)$0.47
Tangible BV / Share (Annual)$6.40
Price vs S&P 500 (52W)-29.48%
Year-to-Date Return68.58%
5-Day Price Return68.24%
EPS Normalized (Annual)$-35.25
ROA (5Y Avg)-54.90%
Net Profit Margin (Annual)-7533.61%
Month-to-Date Return450.32%
Cash Flow / Share (TTM)$-1.41
EBITD / Share (Annual)$-36.27
Operating Margin (Annual)-7929.36%
ROI (5Y Avg)-64.69%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-29.39
P/TBV (Quarterly)0.76x
P/B Ratio (Annual)0.50x
Inventory Turnover (TTM)0.41x
Pretax Margin (TTM)-6980.36%
Book Value / Share (Annual)$9.85
Price vs S&P 500 (13W)257.93%
Beta2.79x
P/FCF (Annual)4.45x
Revenue / Share (TTM)$0.32
ROE (TTM)-164.92%
52-Week Low$1.26
vGradeC
gGradeD
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-4.06est. -3.83
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
2.29
2.29
2.29
2.29
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CODXCo-Diagnostics, Inc. Common Stock | C | D | B | $6.20 |
| SYKStryker Corporation | C | C | D | $299.46 |
| MMM3M Company | C | F | C | $150.93 |
| BSXBoston Scientific Corp. | C | B | F | $47.98 |
| MDLNMedline Inc. Class A common stock | C | D | D | $35.75 |
| BDXBecton, Dickinson and Co. | B | C | C | $145.33 |
| DXCMDexCom, Inc. | C | B | C | $74.87 |
| RMDResMed Inc. | B | B | D | $186.44 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $316.30 |
| SOLVSolventum Corporation | C | D | C | $75.84 |
| PENPenumbra, Inc. | F | C | C | $318.95 |
About
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.